|
Published by: Decision Resources
Published: Sep. 25, 2006 - 197 Pages
Table of Contents
- Table of Contents
- Table of Exhibits
- Executive Summary
- Section 1: Multiple Sclerosis Patient Populations
- Background
- Multiple Sclerosis Prevalence and Diagnosis
- US
- Europe
- Japan
- Section 2: Multiple Sclerosis Treatment Overview
- Major Competitors
- Exisiting Treatments
- Recombinant Interferonâ
- Altered Peptide Ligands
- Chemotherapeutics
- Monoclonal Antibodies
- Corticosteroids
- Immunosuppressants
- Section 3: Major Markets for Multiple Sclerosis Treatment
- Market Overview
- MS Drug Sales by Region
- MS Drug Sales by Class
- Market Forecast
- Key Events
- Drug Pricing
- Formulary Placement
- Recombinant Interferonâ Market
- Altered Peptide Ligand Market
- Chemotherapeutic Market
- Monoclonal Antibody Market
- Corticosteroid Market
- Immunosuppressant Market
- Brands & Strategies: Multiple Sclerosis
- Brands & Strategies: Multiple Sclerosis
- Section 4: Competitive Analysis
- Overview
- Competitive Landscape
- MS Market by Competitor
- Promotional Spending
- Biogen Idec
- Product Portfolio
- Strategic Positioning
- Avonex
- Approval History
- Sales and Market Position
- Avonex Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Tysabri
- Approval History
- Sales and Market Position
- Tysabri Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Biogen Idec MS Pipeline
- Daclizumab
- Rituximab
- BG12
- Pegylated Inferferonâ1a
- LINGO1 Inhibitor
- Teva Pharmaceuticals
- Product Portfolio
- Strategic Positioning
- Copaxone
- Approval History
- Sales and Market Position
- Copaxone Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Teva Pharmaceuticals MS Pipeline
- Laquinimod
- TV5010
- Oral Copaxone
- Brands & Strategies: Multiple Sclerosis
- Brands & Strategies: Multiple Sclerosis
- Serono SA
- Product Portfolio
- Strategic Positioning
- Rebif
- Approval History
- Sales and Market Position
- Rebif Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Novantrone
- Approval History
- Sales and Market Position
- Novantrone Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Serono MS Product Pipeline
- Oral Cladribine
- MMP12 Inhibitor
- JNK Inhibitor
- Interferonâ:Fc
- Osteopontin
- Schering AG
- Product Portfolio
- Strategic Position
- Betaseron
- Approval History
- Sales and Market Position
- Betaseron Competitive Analysis
- Promotional Spending
- Life Cycle Management
- Schering AG MS Pipeline
- Alemtuzumab
- Section 5: Supplementary Market Analysis
- Acronyms and Initialisms
- Methodology
- Epidemiological Forecast Methodology
- Market Forecast Methodology
- Competitive Analysis Methodology
- Brands & Strategies: Multiple Sclerosis
- Table of Exhibits
- Executive Summary
- Exhibit ES1: MS Market Value, Major Markets, 2005-2010
- Exhibit ES2: MS Market by Competitor, 2005 and 2010
- Section 1: Multiple Sclerosis Patient Populations
- Prevalent and Diagnosed MS Cases (Thousands), Major Markets, 2005-2010
- Prevalent and Diagnosed MS Cases (Thousands), US, 2005-2010
- Total Prevalent Cases of MS (Thousands), by Country, Europe, 2005-2010
- Prevalent and Diagnosed MS Cases, Japan, 2005-2010
- Section 2: Multiple Sclerosis Treatment Overview
- Exhibit 21: MS Drugs, by Major Competitor
- Exhibit 22: MS Drugs, by Drug Class
- Section 3: Major Markets for Multiple Sclerosis Treatment
- Exhibit 31: MS Market ($US), Major Markets, 2005-2010 (Graphical Format)
- Exhibit 32: MS Market ($US), Major Markets, 2005-2010 (Tabular Format)
- Exhibit 33: MS Market ($US), by Country, 2005-2010
- Exhibit 34: MS Market, by Country as a % of Total, 2005 and 2010
- Exhibit 35: MS Market ($US), by Drug Class, 2005-2010
- Exhibit 36: Key Events , MS Market, 2005-2010
- Exhibit 37: Price to Treat per Day ($US), Recombinant Interferonâ, 2005-2010
- Exhibit 38: Recombinant Interferonâ Pricing ($US), Brand vs. Generic Price, 2005
- Exhibit 39: Price to Treat per Day ($US), Altered Peptide Ligands, 2005-2010
- Exhibit 310: Price to Treat per Day ($US), Chemotherapeutics, 2005-2010
- Exhibit 311: Chemotherapeutic Pricing ($US), Brand vs. Generic Price, 2005
- Exhibit 312: Price to Treat per Day ($US), Monoclonal Antibodies, 2005-2010
- Exhibit 313: Price to Treat per Day ($US), Corticosteroids, 2005-2010
- Exhibit 314: Corticosteroid Pricing ($US), Brand vs. Generic Price, 2005
- Exhibit 315: Price to Treat per Day ($US), Immunosuppressants, 2005-2010
- Exhibit 316: Immunosuppressant Pricing ($US), Brand vs. Generic Price, 2005
- Exhibit 317: US Formulary Placement of MSIndicated Therapies
- Exhibit 318: Recombinant Interferonâ Market ($US), 2005-2010
- Exhibit 319: Recombinant Interferonâ Market ($US), by Country, 2005-2010
- Exhibit 320: Recombinant Interferonâ Market ($US), by Drug, 2005-2010
- Exhibit 321: Recombinant Interferonâ Branded Market Share, by Brand and
- Country, 2005 and 2010
- Exhibit 322: Altered Peptide Ligand Market ($US), 2005-2010
- Exhibit 323: Altered Peptide Ligand Market ($US), by Country, 2005-2010
- Exhibit 324: Chemotherapeutics Market ($US), 2005-2010
- Exhibit 325: Chemotherapeutics Market ($US), by Country, 2005-2010
- Exhibit 326: Chemotherapeutics Market ($US), by Drug, 2005-2010
- Exhibit 327: Monoclonal Antibody Market ($US), 2005-2010
- Exhibit 328: Monoclonal Antibody Market ($US), by Country, 2005-2010
- Exhibit 329: Monoclonal Antibody Market ($US), by Drug, 2005-2010
- Exhibit 330: Corticosteroid Market ($US), 2005-2010
- Exhibit 331: Corticosteroid Market ($US), by Country, 2005-2010
- Exhibit 332: Corticosteroid Market ($US), by Drug, 2005-2010
- Exhibit 333: Immunosuppressant Market ($US), 2005-2010
- Exhibit 334: Immunosuppressant Market ($US), by Country, 2005-2010
- Exhibit 335: Imuran Market ($US) by Drug, 2005-2010
- Section 4: Competitive Analysis
- Exhibit 41: MS Market Competitive Position, 2005 and 2010
- Exhibit 42: MS Market ($US), by Company, 2005-2010
- Exhibit 43: Promotional Spend for MS Therapies, by Company, 2005
- Exhibit 44: Promotional Spending Among FirstLine MS Therapies, 2005
- Exhibit 45: Summary of Biogen Idec’s MS Product Portfolio
- Exhibit 46: Biogen Idec MS Revenues ($US), by Brand, 2005-2010
- Exhibit 47: Timeline of Avonex Regulatory Approvals in the Seven Major
- Pharmaceutical Markets
- Exhibit 48: Key Clinical Trials Supporting Avonex’ Regulatory Approvals
- Exhibit 49: Timeline of Tysabri Regulatory Approvals in the Seven Major
- Pharmaceutical Markets
- Exhibit 410: Key Clinical Trials Supporting Tysabri’s Regulatory Approvals
- Exhibit 411: Summary of Teva Pharmaceuticals MS Product Portfolio
- Exhibit 412: Timeline of Copaxone Regulatory Approvals in the Seven Major
- Pharmaceutical Markets
- Exhibit 413: Key Clinical Trials Supporting Copaxone’s Regulatory Approvals
- Exhibit 414: Summary of Serono SA’s MS Product Portfolio
- Exhibit 415: Timeline of Rebif Regulatory Approvals in the Seven Major
- Pharmaceutical Markets
- Exhibit 416: Key Clinical Trials Supporting Rebif’s Regulatory Approvals
- Exhibit 417: Key Clinical Trials Supporting Novantrone’s Regulatory Approvals
- Exhibit 418: Summary of Schering AG’s MS Product Portfolio
- Exhibit 419: Timeline of Betaseron Regulatory Approvals in the Seven Major Pharmaceutical Markets
- Exhibit 420: Key Clinical Trials Supporting Betaseron’s Regulatory Approvals
- Exhibit 421: Key Clinical Trials Supporting Betaseron’s Regulatory Approvals,Continued
- Section 5: Supplementary Market Analysis
- Exhibit 51: Total Interferonâ1a (IM) Market ($US), by Country, 2005-2010
- Exhibit 52: Avonex Market ($US), by Country, 2005-2010
- Exhibit 53: Total Interferonâ1a (SC) Market ($US), by Country, 2005-2010
- Exhibit 54: Rebif Market ($US), by Country, 2005-2010
- Exhibit 55: Total Interferonâ1b Market ($US), by Country, 2005-2010
- Exhibit 56: Betaseron Market ($US), by Country, 2005-2010
- Exhibit 57: Total Mitoxantrone Market ($US), by Country, 2005-2010
- Exhibit 58: Novantrone Market ($US), by Country, 2005-2010
- Exhibit 59: Total Cyclophosphamide Market ($US), by Country, 2005-2010
- Exhibit 510: Cytoxan Market ($US), by Country, 2005-2010
- Exhibit 511: Total Methotrexate Market ($US), by Country, 2005-2010
- Exhibit 512: Rheumatrex Market ($US), by Country, 2005-2010
- Exhibit 513: Methylprednisolone Market ($US), by Drug, 2005-2010
- Exhibit 514: SoluMedrol Market ($US), by Country, 2005-2010
- Exhibit 515: Total Prednisone Market ($US), by Country, 2005-2010
- Exhibit 516: Deltasone Market ($US), by Country, 2005-2010
- Exhibit 517: Total Azathioprine Market ($US), by Country, 2005-2010
- Exhibit 518: Imuran Market ($US), by Country, 2005-2010
AbstractIn This Issue...
The market for multiple sclerosis (MS) therapies is dominated by a handful of key players-Biogen Idec, Serono, Schering AG, and Teva-who produce premium priced therapies including interferon-beta (Biogen Idec's Avonex, Serono's Rebif, and Schering AG's Betaseron) and Teva's Copaxone. Despite the commercial success of existing drugs, a high level of unmet clinical need exists, providing ample market opportunity for new treatments that demonstrate improved efficacy, tolerability, and convenience in comparison to currently available treatments.
Questions Answered in This Report
- Competitive dynamics: Market-leading recombinant interferon-beta therapies, such as Biogen Idec's Avonex, Serono's Rebif, and Schering AG's Betaseron, are involved in an intensely competitive arena-from both a within-class perspective and from the other leading MS agent, Teva's altered peptide ligand, Copaxone. How have the leading competitors positioned their brands for success? Which interferon-beta drugs will continue to succeed in the market?
- Market dynamics: The introduction of guidelines for the approval of biosimilar medicinal products in Europe will dramatically affect the market for recombinant interferon-beta. When will biosimilar interferon-beta launch in the major markets? What level of uptake will biosimilars experience and which branded drugs will be most affected?
- Brand dynamics: Following its withdrawal over safety concerns, Biogen Idec's Tysabri has relaunched following an in-depth review of the drug by US and European regulators. How will Tysabri's availability impact the MS market? What effect will safety concerns have on Tysabri's commercial success?
- Key events: Few new drugs have been successfully developed for the treatment of MS in recent years, leaving the market to established competitors. What new drugs are forecast to enter the MS market between 2005 and 2010 and when will they launch? What products are being developed in the major MS competitors' pipelines?
Scope
Markets Covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Market Analysis: Annualized 5-year sales forecasts presented by region, drug class, molecule, and brand for 2005 to 2010, including a breakdown of branded versus generic sales for each market and the impact of key events during the forecast period. Annualized forecast of total prevalent and diagnosed cases for each of the major markets from 2005 to 2010.
Company Analysis: Detailed discussion of major competitors including Biogen Idec, Teva Pharmaceuticals, Serono, and Schering AG. Includes analysis of each company's MS product portfolio, strategic positioning, licensing strategy, post-marketing clinical trials, and development pipeline.
Brand Analysis: The report features an in-depth discussion of leading brands in the MS market, including approval history, sales and market position, SWOT analysis, annualized sales forecast, promotional efforts, and on-going life cycle management initiatives.
Please note: the PDF e-mail from publisher version of this report is for a global site license.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
